Agtr1atm1.1Cof/Agtr1atm1.1Cof
Hprt1tm1(Pck1-cre)Vhh/Hprt1+
involves: 129 * 129P2/OlaHsd
|
abnormal renal water reabsorption |
J:172240
|
|
decreased renal glomerular filtration rate |
J:172240
|
|
decreased systemic arterial systolic blood pressure |
J:172240
|
Agtr1atm1Unc/Agtr1atm1Unc
Agtr1btm1Cof/Agtr1btm1Cof
Hprt1tm1(Ggt1-Agtr1)Cof/Y
involves: 129P2/OlaHsd
|
decreased renin activity |
J:91837
|
|
kidney cyst |
J:91837
|
Agtr1atm1Unc/Agtr1atm1Unc
Hprt1tm1(Ggt1-Agtr1)Cof/Y
involves: 129P2/OlaHsd
|
decreased urine osmolality |
J:91837
|
|
hypotension |
J:91837
|
ApcMin/Apc+
Gpa33tm1(GNAS)Wtsi/Gpa33+
Hprt1tm1(CMV-cre)Brd/?
involves: 129S7/SvEvBrd * C57BL/6J
|
increased intestinal adenoma incidence |
J:168378
|
Arnttm1Bra/Arnttm1Bra
Hprt1tm1(Pck1-cre)Vhh/Y
Vhltm1Jae/Vhltm1Jae
involves: 129 * BALB/c * C57BL/6
|
normal
hematopoietic system phenotype |
J:97652
|
|
hepatic steatosis |
J:97652
|
|
normal
neoplasm |
J:97652
|
|
normal
renal/urinary system phenotype |
J:106705
|
Brf1tm1Arte/Brf1tm1Arte
Hprt1tm1(CAG-BRF1)Gu/Hprt1+
Tg(Cyp1a1-cre)1Dwi/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
normal
liver/biliary system phenotype |
J:285667
|
Dicer1tm1Bdh/Dicer1tm1Bdh
Hprt1tm1(Pck1-cre)Vhh/Y
involves: 129 * 129P2/OlaHsd
|
decreased susceptibility to kidney reperfusion injury |
J:185838
|
|
normal
renal/urinary system phenotype |
J:185838
|
Dysfprmd/Dysfprmd
Hprt1tm2(CAG-Myof)Isrd/Y
involves: 129 * A/J * C57BL/6
|
dystrophic muscle |
J:187293
|
|
normal
homeostasis/metabolism phenotype |
J:187293
|
|
normal
muscle phenotype |
J:187293
|
Dysfprmd/Dysfprmd
Hprt1tm2(CAG-Myof)Isrd/Hprt1tm2(CAG-Myof)Isrd
involves: 129 * A/J * C57BL/6
|
dystrophic muscle |
J:187293
|
|
normal
homeostasis/metabolism phenotype |
J:187293
|
|
normal
muscle phenotype |
J:187293
|
Ext1tm1Vcs/Ext1+
Hprt1tm1(CAG-cre)Mnn/Hprt1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
embryonic lethality during organogenesis, complete penetrance |
J:157599
|
Gdpd2tm1.1Soc/Gdpd2+
Hprt1tm1(CMV-GFP)Nat/Hprt1+
involves: 129/Sv * 129P2 /SvPas * 129S * BALB/cJ * C57BL/6J
|
increased oligodendrocyte number |
J:291492
|
|
increased oligodendrocyte progenitor number |
J:291492
|
Gpa33tm1(GNAS)Wtsi/Gpa33+
Hprt1tm1(CMV-cre)Brd/?
involves: 129S7/SvEvBrd * C57BL/6J
|
normal
digestive/alimentary phenotype |
J:168378
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Hprt1tm6(CAG-fat-1)Geno/Hprt1tm6(CAG-fat-1)Geno
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
abnormal fatty acids level |
J:213660
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Hprt1tm1(Ins2-HBEGF)Herr/Y
Tg(Gcg-rtTA)#Herr/0
Tg(tetO-cre)1Jaw/0
involves: 129X1/SvJ * C57BL/6
|
abnormal pancreatic alpha cell differentiation |
J:159291
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Hprt1tm1(Ins2-HBEGF)Herr/Y
Tg(Ins2-cre/ERT)1Dam/0
involves: 129X1/SvJ * C57BL/6 * CBA
|
abnormal pancreatic islet morphology |
J:159291
|
|
normal
endocrine/exocrine gland phenotype |
J:159291
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
Hprt1tm1(sb-Onco-Array)Peli/Hprt1+
involves: 129S7/SvEvBrd
|
decreased birth body size |
J:166283
|
|
increased hemangioma incidence |
J:166283
|
|
increased hemangiosarcoma incidence |
J:166283
|
|
increased lung adenocarcinoma incidence |
J:166283
|
|
increased lung adenoma incidence |
J:166283
|
|
increased lymphoma incidence |
J:166283
|
|
increased medulloblastoma incidence |
J:166283
|
|
increased rhabdomyosarcoma incidence |
J:166283
|
|
increased skin squamous cell carcinoma incidence |
J:166283
|
|
increased tumor incidence |
J:166283
|
|
perinatal lethality, incomplete penetrance |
J:166283
|
|
postnatal growth retardation |
J:166283
|
|
postnatal lethality, incomplete penetrance |
J:166283
|
|
premature death |
J:166283
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
Hprt1tm1(sb-Onco-Array)Peli/Y
involves: 129S7/SvEvBrd
|
decreased birth body size |
J:166283
|
|
increased hemangioma incidence |
J:166283
|
|
increased hemangiosarcoma incidence |
J:166283
|
|
increased lung adenocarcinoma incidence |
J:166283
|
|
increased lung adenoma incidence |
J:166283
|
|
increased lymphoma incidence |
J:166283
|
|
increased medulloblastoma incidence |
J:166283
|
|
increased rhabdomyosarcoma incidence |
J:166283
|
|
increased skin squamous cell carcinoma incidence |
J:166283
|
|
increased tumor incidence |
J:166283
|
|
perinatal lethality, incomplete penetrance |
J:166283
|
|
postnatal growth retardation |
J:166283
|
|
postnatal lethality, incomplete penetrance |
J:166283
|
|
premature death |
J:166283
|
Gt(ROSA)26Sortm1Fia/Gt(ROSA)26Sor+
Hprt1tm1(CMV-cre)Brd/Hprt1+
Nf1tm1Fcr/Nf1tm1Fcr
involves: 129S/SvEv * 129S/SvEvBrd
|
abnormal dorsal root ganglion morphology |
J:114455
|
|
abnormal enzyme/coenzyme level |
J:114455
|
|
abnormal somatic sensory system morphology |
J:114455
|
|
abnormal sympathetic ganglion morphology |
J:114455
|
|
adrenal medulla hyperplasia |
J:114455
|
|
prenatal lethality, incomplete penetrance |
J:114455
|
Gt(ROSA)26Sortm1Fia/Gt(ROSA)26Sortm1Fia
Hprt1tm1(CMV-cre)Brd/Hprt1+
Nf1tm1Fcr/Nf1tm1Fcr
involves: 129S/SvEv * 129S/SvEvBrd
|
abnormal somatic sensory system morphology |
J:114455
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Hprt1tm1(Pbsn*-cre/ERT2)Jir/Hprt1+
involves: 129P2/OlaHsd * 129S4/SvJaeSor
|
no abnormal phenotype detected |
J:144541
|
Gt(ROSA)26Sortm2(SS18)Mrc/Gt(ROSA)26Sortm2(SS18)Mrc
Hprt1tm1(CAG-cre)Mnn/Hprt1tm1(CAG-cre)Mnn
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
prenatal lethality, complete penetrance |
J:120967
|
Gt(ROSA)26Sortm3(SS18/EGFP)Mrc/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc
Hprt1tm1(CAG-cre)Mnn/Hprt1tm1(CAG-cre)Mnn
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal embryonic tissue morphology |
J:120967
|
|
prenatal lethality, complete penetrance |
J:120967
|
Hif1atm3Rsjo/Hif1atm3Rsjo
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Hprt1tm1(Pck1-cre)Vhh/Y
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ
|
abnormal cell differentiation |
J:130751
|
|
decreased susceptibility to injury |
J:130751
|
|
kidney inflammation |
J:130751
|
|
renal fibrosis |
J:130751
|
Hif1atm3Rsjo/Hif1atm3Rsjo
Hprt1tm1(Pck1-cre)Vhh/Y
Vhltm1Jae/Vhltm1Jae
involves: 129 * BALB/c * C57BL/6
|
abnormal kidney morphology |
J:106705
|
|
abnormal kidney vasculature morphology |
J:106705
|
|
abnormal vasodilation |
J:97652
|
|
hepatic steatosis |
J:97652
|
|
increased hemoglobin content |
J:97652
|
|
increased hepatic hemangioma incidence |
J:97652
|
|
increased vascular endothelial cell number |
J:97652
|
|
kidney cyst |
J:106705
|
|
kidney inflammation |
J:106705
|
|
polycythemia |
J:97652
|
Hprt1b-m3/Y
Impdh1tm1Bmi/Impdh1tm1Bmi
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal lymphopoiesis |
J:85443
|
|
decreased cytotoxic T cell cytolysis |
J:85443
|
|
decreased interleukin-4 secretion |
J:85443
|
|
decreased splenocyte proliferation |
J:85443
|
|
decreased T cell proliferation |
J:85443
|
Hprt1b-m3/Y
Impdh2tm1Bmi/Impdh2+
involves: 129P2/OlaHsd
|
abnormal cytotoxic T cell physiology |
J:86045
|
|
abnormal lymphocyte cell number |
J:86045
|
Hprt1tm1(ACTB-Epor)Unc/Y
involves: 129P2/OlaHsd
|
abnormal definitive hematopoiesis |
J:81859
|
|
normal
hematopoietic system phenotype |
J:81859
|
Hprt1tm1(ACTB-Epor)Unc/Hprt1tm1(ACTB-Epor)Unc
involves: 129P2/OlaHsd
|
abnormal definitive hematopoiesis |
J:81859
|
|
normal
hematopoietic system phenotype |
J:81859
|
Hprt1tm1(ACTB-Opa1)Lsc/Y
involves: 129 * C57BL/6 * C57BL/6J
|
abnormal mitochondrial crista morphology |
J:214492
|
|
abnormal mitochondrial physiology |
J:214492
|
|
decreased susceptibility to injury |
J:214492
|
|
normal
growth/size/body region phenotype |
J:214492
|
Hprt1tm1(AGT)Asku/Y
Tg(REN)64071Sig/?
involves: 129P2/OlaHsd * C57BL/6
|
abnormal circulating angiotensinogen level |
J:143791
|
|
abnormal protein level |
J:143791
|
|
increased circulating angiotensin II level |
J:143791
|
|
increased systemic arterial systolic blood pressure |
J:143791
|
Hprt1tm1(AGT)Sig/Hprt1tm1(AGT)Sig
Tg(hAGT)2041Sig/?
involves: 129P2/OlaHsd * C57BL/6 * SJL/J
|
normal
cardiovascular system phenotype |
J:81310
|
Hprt1tm1(APOA5)Lap/Y
involves: 129P2/OlaHsd * C57BL/6J
|
normal
homeostasis/metabolism phenotype |
J:145098
|
Hprt1tm1(CAG-BRF1)Gu/Hprt1+
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd * FVB/N
|
abnormal translation |
J:285667
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:285667
|
|
premature death |
J:285667
|
Hprt1tm1(CAG-cre)Mnn/Hprt1+
Ptpn11tm1Ckq/Ptpn11+
involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6J
|
abnormal craniofacial development |
J:177285
|
|
abnormal heart tube morphology |
J:177285
|
|
embryonic growth retardation |
J:177285
|
|
embryonic lethality during organogenesis, complete penetrance |
J:177285
|
Hprt1tm1(CAG-Glra3*)Jcme/Y
Pvalbtm1(cre)Arbr/Pvalb+
involves: 129P2/OlaHsd * C57BL/6J
|
abnormal CNS synaptic transmission |
J:207981
|
|
abnormal nervous system electrophysiology |
J:207981
|
|
absent long-term depression |
J:207981
|
|
normal
behavior/neurological phenotype |
J:207981
|
|
increased anxiety-related response |
J:207981
|
Hprt1tm1(CAG-Glra3*)Jcme/Y
Tg(Camk2a-cre)2Gsc/0
involves: 129P2/OlaHsd * C57BL/6J * FVB/N
|
abnormal nervous system electrophysiology |
J:207981
|
|
abnormal object recognition memory |
J:207981
|
|
abnormal spatial reference memory |
J:207981
|
|
abnormal spatial working memory |
J:207981
|
|
abnormal synaptic glutamate release |
J:207981
|
|
increased susceptibility to pharmacologically induced seizures |
J:207981
|
|
normal
nervous system phenotype |
J:207981
|
Hprt1tm1(CAG-Gys1*)Jjg/?
Myl1tm1(cre)Sjb/Myl1+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
abnormal cellular respiration |
J:244440
|
|
abnormal response to exercise |
J:244440
|
|
decreased aerobic running capacity |
J:244440
|
|
impaired exercise endurance |
J:244440
|
|
increased skeletal muscle glycogen level |
J:244440
|
Hprt1tm1(CAG-Gys1*)Jjg/?
Tg(Nes-cre)1Kag/?
involves: 129P2/OlaHsd
|
impaired autophagy |
J:210491
|
|
increased brain glycogen level |
J:210491
|
Hprt1tm1(CAG-mCherry/Villin)Syr/?
Vil1tm1Syr/Vil1tm1Syr
Tg(Vil1-cre/ERT2)23Syr/0
involves: C57BL/6
|
normal
homeostasis/metabolism phenotype |
J:196199
|
Hprt1tm1(CAG-NRIP1)Vcls/Hprt1+
involves: 129 * C57BL/6
|
abnormal enterocyte proliferation |
J:211324
|
|
abnormal Paneth cell morphology |
J:211324
|
|
abnormal small intestine morphology |
J:211324
|
|
decreased enterocyte apoptosis |
J:211324
|
Hprt1tm1(CAG-NRIP1)Vcls/Y
involves: 129 * C57BL/6
|
abnormal enterocyte proliferation |
J:211324
|
|
abnormal Paneth cell morphology |
J:211324
|
|
abnormal small intestine morphology |
J:211324
|
|
decreased enterocyte apoptosis |
J:211324
|
Hprt1tm1(CAG-Sox9,-EGFP)Akis/Y
Tbx18tm4(cre)Akis/Tbx18+
involves: 129/Sv * 129S1/SvImJ * NMRI
|
abnormal ureter morphology |
J:166547
|
|
abnormal ureter smooth muscle morphology |
J:166547
|
Hprt1tm1(CAG-Tgfbr1*)Lba/Hprt1tm1(CAG-Tgfbr1*)Lba
Tg(Cd4-cre)1Cwi/0
involves: 129 * C57BL/6 * DBA/2
|
abnormal T cell activation |
J:148747
|
Hprt1tm1(CAG-Tgfbr1*)Lba/Hprt1tm1(CAG-Tgfbr1*)Lba
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
Tg(Cd4-cre)1Cwi/0
involves: 129 * 129S6/SvEvTac * C57BL/6 * DBA/2
|
normal
immune system phenotype |
J:148747
|
Hprt1tm1(CAG-Tgfbr1*)Lba/Y
Tg(Cd4-cre)1Cwi/0
involves: 129 * C57BL/6 * DBA/2
|
abnormal T cell activation |
J:148747
|
Hprt1tm1(CAG-Tgfbr1*)Lba/Y
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
Tg(Cd4-cre)1Cwi/0
involves: 129 * 129S6/SvEvTac * C57BL/6 * DBA/2
|
normal
immune system phenotype |
J:148747
|
Hprt1tm1(Camk2a-APP*Swe*Lon,-MAPT*P301L*R406W)Geno/Hprt1+
Tg(PSEN1)5Dbo/0
involves: 129P2/OlaHsd
|
abnormal brain wave pattern |
J:180977
|
|
abnormal glucose homeostasis |
J:180977
|
|
abnormal learning/memory/conditioning |
J:180977
|
|
abnormal long-term potentiation |
J:180977
|
|
abnormal motor coordination/balance |
J:180977
|
|
abnormal spatial reference memory |
J:180977
|
|
abnormal spatial working memory |
J:180977
|
|
decreased paired-pulse facilitation |
J:180977
|
|
fragmentation of sleep/wake states |
J:180977
|
|
hyperactivity |
J:180977
|
|
impaired short-term object recognition memory |
J:180977
|
|
normal
nervous system phenotype |
J:180977
|
Hprt1tm1(CUX1)Anep/Hprt1+
either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
abnormal hematopoietic system morphology/development |
J:113393
|
|
abnormal hematopoietic system physiology |
J:113393
|
|
abnormal liver morphology |
J:113393
|
|
abnormal lung morphology |
J:113393
|
|
abnormal spleen white pulp morphology |
J:113393
|
|
abnormal splenic cell ratio |
J:113393
|
|
anemia |
J:113393
|
|
decreased B cell number |
J:113393
|
|
decreased erythrocyte cell number |
J:113393
|
|
decreased hematocrit |
J:113393
|
|
decreased mean corpuscular hemoglobin concentration |
J:113393
|
|
enlarged lymph nodes |
J:113393
|
|
enlarged spleen |
J:113393
|
|
increased leukocyte cell number |
J:113393
|
|
increased neutrophil cell number |
J:113393
|
|
myeloid hyperplasia |
J:113393
|
|
spleen hyperplasia |
J:113393
|
Hprt1tm1(CUX1)Anep/Hprt1+
FVB.129P2-Hprt1tm1(CUX1)Anep
|
abnormal branching of the mammary ductal tree |
J:152682
|
|
increased mammary adenocarcinoma incidence |
J:152682
|
|
increased mammary gland tumor incidence |
J:152682
|
Hprt1tm1(Ggt1-Agtr1)Cof/Y
involves: 129P2/OlaHsd
|
no abnormal phenotype detected |
J:91837
|
Hprt1tm1(H1-RNAi:Tmsb4x)Prri/Hprt1+
Tg(Tek-cre)1Ywa/0
involves: C57BL/6 * SJL
|
abnormal blood vessel morphology |
J:195902
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:195902
|
|
hemopericardium |
J:195902
|
|
internal hemorrhage |
J:195902
|
|
intracranial hemorrhage |
J:195902
|
|
lethality throughout fetal growth and development, incomplete penetrance |
J:195902
|
Hprt1tm1(Ins2-HBEGF)Herr/Y
involves: 129 * C57BL/6
|
abnormal pancreatic beta cell physiology |
J:159291
|
|
abnormal pancreatic islet morphology |
J:159291
|
|
decreased insulin secretion |
J:159291
|
|
decreased pancreatic beta cell mass |
J:159291
|
|
decreased pancreatic beta cell number |
J:159291
|
|
hyperglycemia |
J:159291
|
|
increased insulin secretion |
J:159291
|
|
increased pancreatic beta cell mass |
J:159291
|
|
ketoacidosis |
J:159291
|
|
polydipsia |
J:159291
|
|
polyuria |
J:159291
|
|
premature death |
J:159291
|
|
weight loss |
J:159291
|
Hprt1tm1(Ins2-HBEGF)Herr/Hprt1tm1(Ins2-HBEGF)Herr
involves: 129 * C57BL/6
|
hyperglycemia |
J:159291
|
Hprt1tm1(Ins2-HBEGF)Herr/Y
Tg(Gcg-HBEGF)#Herr/0
involves: 129 * C57BL/6
|
normal
endocrine/exocrine gland phenotype |
J:159291
|
Hprt1tm1(MAPT)Dph/Y
involves: 129P2/OlaHsd * C57BL/6
|
abnormal autophagy |
J:263643
|
|
abnormal hippocampus morphology |
J:263643
|
|
abnormal hippocampus physiology |
J:263643
|
|
abnormal skeletal muscle fiber morphology |
J:263643
|
|
normal
behavior/neurological phenotype |
J:263643
|
|
decreased grip strength |
J:263643
|
|
normal
growth/size/body region phenotype |
J:263643
|
|
impaired coordination |
J:263643
|
|
impaired spatial learning |
J:263643
|
|
kyphosis |
J:263643
|
|
limb grasping |
J:263643
|
|
paresis |
J:263643
|
|
premature death |
J:263643
|
|
skeletal muscle fiber degeneration |
J:263643
|
Hprt1tm1(Nphs1-CMIP)Dsah/Hprt1+
B6.Cg-Hprt1tm1(Nphs1-CMIP)Dsah
|
abnormal podocyte morphology |
J:185411
|
|
abnormal podocyte slit diaphragm morphology |
J:185411
|
|
absent podocyte slit diaphragm |
J:185411
|
|
albuminuria |
J:185411
|
|
expanded mesangial matrix |
J:185411
|
|
glomerulosclerosis |
J:185411
|
|
increased mesangial cell number |
J:185411
|
|
increased urine protein level |
J:185411
|
|
podocyte foot process effacement |
J:185411
|
Hprt1tm1(Pbsn*-cre/ERT2)Jir/Y
Ptentm2Mak/Ptentm2Mak
involves: 129P2/OlaHsd * C57BL/6
|
increased prostate gland adenocarcinoma incidence |
J:144357
|
|
increased prostate intraepithelial neoplasia incidence |
J:144357
|
Hprt1tm1(Pck1-cre)Vhh/Hprt1+
Tg(CAG-lacZ,-Miox)#Ysk/0
involves: 129P2/OlaHsd * C57BL/6J
|
increased blood urea nitrogen level |
J:266834
|
|
increased circulating creatinine level |
J:266834
|
|
increased renal tubule apoptosis |
J:266834
|
|
increased susceptibility to injury |
J:266834
|
|
oxidative stress |
J:266834
|
Hprt1tm1(Pck1-cre)Vhh/Y
Vhltm1Jae/Vhltm1Jae
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6
|
abnormal kidney morphology |
J:106705
|
|
abnormal kidney vasculature morphology |
J:106705
|
|
abnormal vasodilation |
J:97652
|
|
hepatic steatosis |
J:97652
|
|
increased hemoglobin content |
J:97652
|
|
increased hepatic hemangioma incidence |
J:97652
|
|
increased vascular endothelial cell number |
J:97652
|
|
kidney cyst |
J:106705
|
|
kidney inflammation |
J:106705
|
|
polycythemia |
J:97652
|
Hprt1tm1(Rcan1)Zyga/Hprt1+
B6.129P2-Hprt1tm1(Rcan1)Zyga
|
abnormal megakaryocyte progenitor cell morphology |
J:197570
|
|
decreased tumor growth/size |
J:150286
|
|
decreased vascular endothelial cell proliferation |
J:150286
|
|
increased megakaryocyte cell number |
J:197570
|
|
thrombocytosis |
J:197570
|
Hprt1tm1(tetO-EGFP/Rac1*)Shaw/Y
involves: 129S4/SvJae * C57BL/6
|
normal
renal/urinary system phenotype |
J:206088
|
Hprt1tm1(tetO-EGFP/Rac1*)Shaw/Y
Tg(Nphs1-rtTA*3G)8Jhm/0
involves: 129S4/SvJae * C57BL/6
|
increased urine protein level |
J:206088
|
|
normal
renal/urinary system phenotype |
J:206088
|
Hprt1tm1(tetO-EGFP/Rac1*)Shaw/Y
Tg(NPHS2-rtTA2*M2)1Jbk/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
increased urine protein level |
J:206088
|
|
podocyte foot process effacement |
J:206088
|
Hprt1tm1(tetO-Runx1,-EGFP)Enk/Hprt1+
Sox10tm2(rtTA)Weg/Sox10+
involves: 129P2/OlaHsd
|
abnormal skin pigmentation |
J:165939
|
|
decreased birth body size |
J:165939
|
|
hyperresponsive to tactile stimuli |
J:165939
|
|
megacolon |
J:165939
|
|
postnatal lethality, complete penetrance |
J:165939
|
|
small dorsal root ganglion |
J:165939
|
Hprt1tm1(UAS-Bmp4)Bhr/Hprt1+
Tg(Wnt1-GAL4)1Rth/0
involves: 129S7/SvEvBrd * C57BL/6
|
embryonic growth retardation |
J:91296
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:91296
|
|
exencephaly |
J:91296
|
|
hemorrhage |
J:91296
|
Hprt1tm1(UBC-UBB)Rrk/Hprt1tm1(UBC-UBB)Rrk
Ubctm1Rrk/Ubctm1Rrk
involves: 129 * C57BL/6J
|
normal
cellular phenotype |
J:122574
|
|
decreased embryo size |
J:122574
|
|
normal
liver/biliary system phenotype |
J:122574
|
|
perinatal lethality, complete penetrance |
J:122574
|
Hprt1tm1(UBC-UBB)Rrk/Y
Ubctm1Rrk/Ubctm1Rrk
involves: 129 * C57BL/6J
|
normal
cellular phenotype |
J:122574
|
|
decreased embryo size |
J:122574
|
|
normal
liver/biliary system phenotype |
J:122574
|
|
perinatal lethality, complete penetrance |
J:122574
|
Hprt1tm1.1(CAG-DLL1*,-Venus)Gos/Y
involves: 129P2/OlaHsd * C57BL/6J * CD-1
|
no abnormal phenotype detected |
J:209193
|
Hprt1tm1.1(CAG-DLL1*,-Venus)Gos/Hprt1tm1.1(CAG-DLL1*,-Venus)Gos
involves: 129P2/OlaHsd * C57BL/6J * CD-1
|
no abnormal phenotype detected |
J:209193
|
Hprt1tm1.1(CAG-Smpd1)Jhkh/Hprt1+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal ceramide level |
J:199833
|
|
abnormal depression-related behavior |
J:199833
|
|
abnormal neuron differentiation |
J:199833
|
|
abnormal physiological response to xenobiotic |
J:199833
|
Hprt1tm1Detl/Y
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
|
abnormal brain morphology |
J:44728
|
|
abnormal gait |
J:44728
|
|
abnormal motor capabilities/coordination/movement |
J:44728
|
|
ataxia |
J:44728
|
|
convulsive seizures |
J:44728
|
|
decreased exploration in new environment |
J:44728
|
|
decreased vertical activity |
J:44728
|
|
hepatic steatosis |
J:44728
|
|
impaired coordination |
J:44728
|
|
increased body weight |
J:44728
|
|
jerky movement |
J:44728
|
|
limb grasping |
J:44728
|
|
neuronal intranuclear inclusions |
J:44728
|
|
premature death |
J:44728
|
|
seizures |
J:44728
|
|
testicular atrophy |
J:44728
|
|
tremors |
J:44728
|
Hprt1tm1Detl/Hprt1tm1Detl
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
|
abnormal brain morphology |
J:44728
|
|
abnormal gait |
J:44728
|
|
abnormal motor capabilities/coordination/movement |
J:44728
|
|
ataxia |
J:44728
|
|
convulsive seizures |
J:44728
|
|
decreased exploration in new environment |
J:44728
|
|
decreased vertical activity |
J:44728
|
|
hepatic steatosis |
J:44728
|
|
impaired coordination |
J:44728
|
|
jerky movement |
J:44728
|
|
limb grasping |
J:44728
|
|
neuronal intranuclear inclusions |
J:44728
|
|
premature death |
J:44728
|
|
seizures |
J:44728
|
|
tremors |
J:44728
|
Hprt1tm1Dhm/Y
involves: 129P2/OlaHsd
|
abnormal cardiac muscle relaxation |
J:106044
|
|
abnormal myocardial fiber physiology |
J:106044
|
|
cardiac hypertrophy |
J:106044
|
|
decreased cardiac muscle contractility |
J:106044
|
|
decreased ventricle muscle contractility |
J:91410
|
|
increased heart weight |
J:91410
|
Hprt1tm1Dhm/Hprt1tm1Dhm
involves: 129P2/OlaHsd
|
abnormal cardiac muscle relaxation |
J:106044
|
|
abnormal myocardial fiber physiology |
J:106044
|
|
cardiac hypertrophy |
J:106044
|
|
decreased cardiac muscle contractility |
J:106044
|
|
decreased ventricle muscle contractility |
J:91410
|
|
increased heart weight |
J:91410
|
Hprt1tm1Dhm/Hprt1tm1Dhm
Plntm1Egk/Plntm1Egk
involves: 129P2/OlaHsd * 129S2/SvPas
|
abnormal cardiac muscle relaxation |
J:106044
|
|
abnormal myocardial fiber physiology |
J:106044
|
|
increased cardiac muscle contractility |
J:106044
|
Hprt1tm1Dhm/Y
Plntm1Egk/Plntm1Egk
involves: 129P2/OlaHsd * 129S2/SvPas
|
abnormal cardiac muscle relaxation |
J:106044
|
|
abnormal myocardial fiber physiology |
J:106044
|
|
increased cardiac muscle contractility |
J:106044
|
Hprt1tm1Dwm/Y
involves: 129P2/OlaHsd
|
phenotypic reversion |
J:161048
|
Hprt1tm2(AGT)Asku/Y
Tg(REN)64071Sig/?
involves: 129P2/OlaHsd * C57BL/6
|
abnormal circulating angiotensinogen level |
J:143791
|
|
abnormal protein level |
J:143791
|
|
increased circulating angiotensin II level |
J:143791
|
|
increased systemic arterial systolic blood pressure |
J:143791
|
Hprt1tm2(AGT)Sig/Y
involves: 129P2/OlaHsd * C57BL/6J
|
increased systemic arterial blood pressure |
J:81515
|
Hprt1tm2(AGT)Sig/Hprt1tm2(AGT)Sig
involves: 129P2/OlaHsd * C57BL/6J
|
increased systemic arterial blood pressure |
J:81515
|
Hprt1tm2(AGT)Sig/Hprt1tm2(AGT)Sig
Tg(hAGT)2041Sig/?
involves: 129P2/OlaHsd * C57BL/6 * SJL/J
|
increased heart weight |
J:81310
|
Hprt1tm2(AGT)Sig/Y
Tg(hAGT)2041Sig/?
involves: 129P2/OlaHsd * C57BL/6 * SJL/J
|
increased systemic arterial blood pressure |
J:81310
|
Hprt1tm2(APOA5)Lap/Y
involves: 129P2/OlaHsd * C57BL/6J
|
normal
homeostasis/metabolism phenotype |
J:145098
|
Hprt1tm2(CAG-mCherry/Villin*)Syr/?
Vil1tm1Syr/Vil1tm1Syr
Tg(Vil1-cre/ERT2)23Syr/0
involves: C57BL/6
|
impaired wound healing |
J:196199
|
Hprt1tm2(CAG-Myof)Isrd/Y
involves: 129 * C57BL/6
|
normal
muscle phenotype |
J:187293
|
Hprt1tm2(CAG-Myof)Isrd/Hprt1tm2(CAG-Myof)Isrd
involves: 129 * C57BL/6
|
normal
muscle phenotype |
J:187293
|
Hprt1tm2(CAG-Ppp1r3c)Jjg/?
Not Specified
|
impaired autophagy |
J:210491
|
|
increased brain glycogen level |
J:210491
|
Hprt1tm2(CAG-Ppp1r3c)Jjg/?
Nhlrc1tm1(KOMP)Vlcg/Nhlrc1tm1(KOMP)Vlcg
involves: C57BL/6NTac
|
impaired autophagy |
J:210491
|
|
increased brain glycogen level |
J:210491
|
Hprt1tm2(CAG-TBX2,-EGFP)Akis/Hprt1+
Tg(Myh6-cre)2182Mds/0
involves: 129 * FVB/N * NMRI
|
abnormal heart development |
J:181526
|
Hprt1tm2(CUX1)Anep/Hprt1+
either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
normal
immune system phenotype |
J:113393
|
Hprt1tm2(CUX1)Anep/Hprt1+
FVB.129P2-Hprt1tm2(CUX1)Anep
|
normal
endocrine/exocrine gland phenotype |
J:152682
|
|
increased mammary adenocarcinoma incidence |
J:152682
|
|
increased mammary gland tumor incidence |
J:152682
|
Hprt1tm2(Pgk1-Pac/TK)Brd/Y
involves: 129S7/SvEvBrd
|
no abnormal phenotype detected |
J:99258
|
Hprt1tm2(Pgk1-Pac/TK)Brd/Y
involves: 129S7/SvEvBrd * C57BL/6J
|
normal
reproductive system phenotype |
J:99558
|
Hprt1tm2(Pgk1-Pac/TK)Brd/Hprt1+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S7/SvEvBrd * C57BL/6 * CBA
|
abnormal aortic arch morphology |
J:130481
|
|
abnormal aortic valve morphology |
J:130481
|
|
abnormal cardiac outflow tract development |
J:130481
|
|
abnormal cardiovascular development |
J:130481
|
|
abnormal craniofacial morphology |
J:130481
|
|
abnormal heart morphology |
J:130481
|
|
abnormal heart right ventricle morphology |
J:130481
|
|
abnormal heart valve morphology |
J:130481
|
|
abnormal mitral valve morphology |
J:130481
|
|
abnormal neural crest cell morphology |
J:130481
|
|
abnormal pharyngeal arch mesenchyme morphology |
J:130481
|
|
congestive heart failure |
J:130481
|
|
decreased embryo size |
J:130481
|
|
double outlet right ventricle |
J:130481
|
|
edema |
J:130481
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:130481
|
|
enlarged heart |
J:130481
|
|
heart right ventricle outflow tract stenosis |
J:130481
|
|
interrupted aortic arch |
J:130481
|
|
interrupted aortic arch, type b |
J:130481
|
|
interrupted aortic arch, type c |
J:130481
|
|
overriding aortic valve |
J:130481
|
|
pericardial effusion |
J:130481
|
|
persistent truncus arteriosus |
J:130481
|
|
pulmonary valve stenosis |
J:130481
|
|
retroesophageal right subclavian artery |
J:130481
|
|
right aortic arch |
J:130481
|
|
transposition of great arteries |
J:130481
|
|
ventricular septal defect |
J:130481
|
Hprt1tm2(Pgk1-Pac/TK)Brd/Y
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S7/SvEvBrd * C57BL/6 * CBA
|
abnormal aortic arch morphology |
J:130481
|
|
abnormal aortic valve morphology |
J:130481
|
|
abnormal cardiac outflow tract development |
J:130481
|
|
abnormal cardiovascular development |
J:130481
|
|
abnormal craniofacial morphology |
J:130481
|
|
abnormal heart morphology |
J:130481
|
|
abnormal heart right ventricle morphology |
J:130481
|
|
abnormal heart valve morphology |
J:130481
|
|
abnormal mitral valve morphology |
J:130481
|
|
abnormal neural crest cell morphology |
J:130481
|
|
abnormal pharyngeal arch mesenchyme morphology |
J:130481
|
|
congestive heart failure |
J:130481
|
|
decreased embryo size |
J:130481
|
|
double outlet right ventricle |
J:130481
|
|
edema |
J:130481
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:130481
|
|
enlarged heart |
J:130481
|
|
heart right ventricle outflow tract stenosis |
J:130481
|
|
interrupted aortic arch |
J:130481
|
|
interrupted aortic arch, type b |
J:130481
|
|
interrupted aortic arch, type c |
J:130481
|
|
overriding aortic valve |
J:130481
|
|
pericardial effusion |
J:130481
|
|
persistent truncus arteriosus |
J:130481
|
|
pulmonary valve stenosis |
J:130481
|
|
retroesophageal right subclavian artery |
J:130481
|
|
right aortic arch |
J:130481
|
|
transposition of great arteries |
J:130481
|
|
ventricular septal defect |
J:130481
|
Hprt1tm2(UAS-Bmp4)Bhr/Hprt1+
Tg(Wnt1-GAL4)1Rth/0
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal blood vessel morphology |
J:91296
|
|
abnormal eye morphology |
J:91296
|
|
embryonic growth retardation |
J:91296
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:91296
|
|
exencephaly |
J:91296
|
|
hemorrhage |
J:91296
|
Hprt1tm2.1(CAG-DLL1*,-Venus)Gos/Y
involves: 129P2/OlaHsd * C57BL/6J * CD-1
|
no abnormal phenotype detected |
J:209193
|
Hprt1tm2.1(CAG-DLL1*,-Venus)Gos/Hprt1tm2.1(CAG-DLL1*,-Venus)Gos
involves: 129P2/OlaHsd * C57BL/6J * CD-1
|
no abnormal phenotype detected |
J:209193
|
Hprt1tm2Brd/Hprt1+
Myo7a4626SB/Myo7a4626SB
involves: 129S7/SvEvBrd * BALB/cRl * C3H * C57BL/6J * CBA/Ca
|
normal
hearing/vestibular/ear phenotype |
J:132633
|
Hprt1tm3(APOA5)Lap/Hprt1tm3(APOA5)Lap
involves: 129P2/OlaHsd * C57BL/6J
|
normal
homeostasis/metabolism phenotype |
J:145098
|
Hprt1tm3(CAG-Tbx18,-Venus)Akis/Y
Tbx18tm4(cre)Akis/Tbx18+
involves: 129S1/SvImJ * NMRI
|
normal
cardiovascular system phenotype |
J:210076
|
|
postnatal lethality, complete penetrance |
J:210076
|
Hprt1tm3.1(CAG-DLL1*,-Venus)Gos/Y
involves: 129P2/OlaHsd * C57BL/6J * CD-1
|
no abnormal phenotype detected |
J:209193
|
Hprt1tm3.1(CAG-DLL1*,-Venus)Gos/Hprt1tm3.1(CAG-DLL1*,-Venus)Gos
involves: 129P2/OlaHsd * C57BL/6J * CD-1
|
no abnormal phenotype detected |
J:209193
|
Hprt1tm3Brd/Hprt1+
Myo7a4626SB/Myo7a4626SB
involves: 129S7/SvEvBrd * BALB/cRl * C3H * C57BL/6J * CBA/Ca
|
normal
hearing/vestibular/ear phenotype |
J:132633
|
Hprt1tm4(CAG-Tbx18*,-Venus)Akis/Y
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Tbx18tm4(cre)Akis/Tbx18+
involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * NMRI
|
abnormal epicardium development |
J:210076
|
Hprt1tm4(CAG-Tbx18*,-Venus)Akis/Y
Tbx18tm4(cre)Akis/Tbx18+
involves: 129S1/SvImJ * NMRI
|
abnormal pericardium morphology |
J:210076
|
|
abnormal sinus venosus morphology |
J:210076
|
|
normal
cardiovascular system phenotype |
J:210076
|
|
decreased fetal cardiomyocyte proliferation |
J:210076
|
|
heart hypoplasia |
J:210076
|
|
lethality throughout fetal growth and development, complete penetrance |
J:210076
|
|
thin ventricle myocardium compact layer |
J:210076
|
Hprt1tm4(Tek-IGF1R)Geno/Y
B6.129P2-Hprt1tm4(Tek-IGF1R)Geno
|
abnormal nitric oxide homeostasis |
J:208523
|
|
abnormal vascular endothelial cell migration |
J:208523
|
|
abnormal vascular endothelial cell physiology |
J:208523
|
|
abnormal vascular wound healing |
J:208523
|
|
normal
cardiovascular system phenotype |
J:208523
|
|
normal
homeostasis/metabolism phenotype |
J:208523
|
|
increased vasoconstriction |
J:208523
|
Hprt1tm5(Camk2a-BACE1)Geno/Y
B6.129P2-Hprt1tm5(Camk2a-BACE1)Geno
|
abnormal habituation to a new environment |
J:215577
|
|
abnormal motor coordination/balance |
J:215577
|
|
abnormal nervous system morphology |
J:215577
|
|
abnormal spatial reference memory |
J:215577
|
|
astrocytosis |
J:215577
|
|
decreased anxiety-related response |
J:215577
|
|
decreased body weight |
J:215577
|
|
decreased locomotor activity |
J:215577
|
|
impaired social transmission of food preference |
J:215577
|
|
impaired spatial working memory |
J:215577
|
|
neurodegeneration |
J:215577
|
|
neuronal intranuclear inclusions |
J:215577
|
|
short stride length |
J:215577
|
|
normal
taste/olfaction phenotype |
J:215577
|
Hprt1tm5(Camk2a-BACE1)Geno/Hprt1tm5(Camk2a-BACE1)Geno
B6.129P2-Hprt1tm5(Camk2a-BACE1)Geno
|
abnormal habituation to a new environment |
J:215577
|
|
abnormal motor coordination/balance |
J:215577
|
|
abnormal nervous system morphology |
J:215577
|
|
abnormal spatial reference memory |
J:215577
|
|
astrocytosis |
J:215577
|
|
decreased anxiety-related response |
J:215577
|
|
decreased body weight |
J:215577
|
|
decreased locomotor activity |
J:215577
|
|
impaired social transmission of food preference |
J:215577
|
|
impaired spatial working memory |
J:215577
|
|
neurodegeneration |
J:215577
|
|
neuronal intranuclear inclusions |
J:215577
|
|
short stride length |
J:215577
|
|
normal
taste/olfaction phenotype |
J:215577
|
Hprt1tm6(CAG-fat-1)Geno/Y
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
abnormal fatty acids level |
J:213660
|
Hprt1tm86(NR2E1,bEMS223)Ems/Y
B6.Cg-Hprt1tm86(NR2E1,bEMS223)Ems
|
abnormal neuronal precursor proliferation |
J:183689
|
|
normal
cardiovascular system phenotype |
J:183689
|
|
normal
nervous system phenotype |
J:183689
|
|
normal
vision/eye phenotype |
J:183689
|
Hprt1tm86(NR2E1,bEMS223)Ems/Y
Nr2e1frc/Nr2e1frc
involves: 129P2/OlaHsd * 129S1/SvImJ * C57BL/6
|
abnormal cerebral hemisphere morphology |
J:183689
|
|
abnormal neuronal precursor proliferation |
J:183689
|
|
normal
cardiovascular system phenotype |
J:183689
|
|
small olfactory bulb |
J:183689
|
|
normal
vision/eye phenotype |
J:183689
|
Mcoln3tm1.2Hels/Mcoln3tm1.2Hels
Hprt1tm1(CAG-cre)Mnn/?
involves: 129X1/SvJ * C57BL/6 * FVB/N
|
normal
hearing/vestibular/ear phenotype |
J:167711
|
|
normal
reproductive system phenotype |
J:167711
|
Mioxtm1Ysk/Mioxtm1Ysk
Hprt1tm1(Pck1-cre)Vhh/Hprt1+
B6.129-Mioxtm1Ysk Hprt1tm1(Pck1-cre)Vhh
|
decreased susceptibility to injury |
J:266834
|
|
decreased susceptibility to weight loss |
J:266834
|
Pdss2tm1Dalg/Pdss2tm1Dalg
Hprt1tm1(Pck1-cre)Vhh/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
normal
homeostasis/metabolism phenotype |
J:136670
|
|
normal
renal/urinary system phenotype |
J:136670
|
Phox2btm1Rth/Phox2b+
Hprt1tm1(CAG-cre)Mnn/?
involves: 129 * 129S1/Sv * C57BL/6
|
abnormal facial nerve morphology |
J:331513
|
|
abnormal innervation |
J:331513
|
|
abnormal locus ceruleus morphology |
J:331513
|
|
abnormal nervous system electrophysiology |
J:331513
|
|
abnormal neuron morphology |
J:331513
|
|
abnormal trigeminal V mesencephalic nucleus morphology |
J:331513
|
|
abnormal vagus nerve morphology |
J:331513
|
|
cyanosis |
J:331513
|
|
perinatal lethality, complete penetrance |
J:331513
|
|
respiratory failure |
J:331513
|
Porcntm1.1Vdv/Porcn+
Hprt1tm1(CAG-cre)Mnn/Hprt1+
involves: 129S/Sv * C57BL/6J
|
abnormal ventral body wall morphology |
J:186934
|
|
caudal body truncation |
J:186934
|
|
embryonic growth retardation |
J:186934
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:186934
|
|
open neural tube |
J:186934
|
|
prenatal lethality, complete penetrance |
J:186934
|
Thrbtm1Mkni/Thrb+
Hprt1tm1(TG-cre)1Sasr/Y
involves: 129/Sv * C57BL/6
|
decreased thyroid gland weight |
J:208718
|
Thrbtm1Mkni/Thrbtm1Mkni
Hprt1tm1(TG-cre)1Sasr/Y
involves: 129/Sv * C57BL/6
|
abnormal thyroid hormone level |
J:208718
|
|
decreased circulating thyroid-stimulating hormone level |
J:208718
|
|
decreased thyroid gland weight |
J:208718
|
|
normal
growth/size/body region phenotype |
J:208718
|
|
increased circulating levels of thyroid hormone |
J:208718
|
|
increased circulating thyroxine level |
J:208718
|
|
increased thyroxine level |
J:208718
|
Excel File
Analysis Tools